Table 2.

Characteristics of included studies.

Study	Enrollment period	Sample size		Intervention		Evaluation index
		Experimental group	Control group	Experimental group	Control group
Bao WL 2011	2007.8–2010.10	45	48	GP + cinobufacini injection	GP	Adverse event, clinical efficacy, KPS, weight change
Cao J 2016	2013.1–2015.1	40	40	DP + cinobufacini injection	DP	Adverse event, clinical efficacy, median survival time, survival rate
Duan HL 2018	2015.1–2017.1	30	30	Docetaxel + cinobufacini injection	Docetaxel	Adverse event, clinical efficacy, tumor marker
He YZ 2016	2013.1–2015.1	42	50	TP + cinobufacini injection	TP	Adverse event, clinical efficacy, tumor marker
Huang ZF 2010	2006.8–2009.8	30	30	GC + cinobufacini injection	GC	Adverse event, clinical efficacy, Immunity, KPS, Zhengzhou score
Ji SG 2017	2014.6–2016.12	49	49	DC + cinobufacini injection	DC	Adverse event, clinical efficacy, KPS, mPFS
Li M 2007	2002.6–2006.6	32	32	NP/GP + cinobufacini injection	NP/GP	Clinical efficacy, KPS, Mean survival time, survival rate, symptoms, weight change
Li XQ 2009	2005.8–2007.10	30	32	NP + cinobufacini injection	NP	Adverse event, clinical efficacy, KPS, weight change
Miao CL 2007	2002.6–2005.2	43	44	NP + cinobufacini injection	NP	Adverse event, clinical efficacy, KPS, median response duration, median survival time, pain relief
Qi RF 2011	2008.6–2010.6	30	30	GP/NP/TP + cinobufacini injection	GP/NP/TP	Adverse event, clinical efficacy
Qiao YX 2006	1999.1–2004.1	60	60	NP + cinobufacini injection	NP	Adverse event, clinical efficacy, Immunity, KPS, survival rate, weight change
Sun J 2002	1998.2–2000.12	45	37	VP + cinobufacini injection	VP	Adverse event, clinical efficacy, KPS
Sun Y 2008	2003.5–2005.2	32	30	NI + cinobufacini injection	NI	Adverse event, clinical efficacy, KPS
Wang WR 2013	2010.6–2011.12	45	45	TP + cinobufacini injection	TP	Adverse event, clinical efficacy, KPS, QLQ-C30 score, tumor marker
Yang XF 2006	2003.8–2005.8	30	30	NP + cinobufacini injection	NP	Adverse event, clinical efficacy, KPS, pain relief
Yao J 2018	2013.1–2017.1	100	100	DP + cinobufacini injection	DP	Adverse event, immunity, pain relief, QLQ-C30 score, survival rate, Zhengzhou score
Yao SL 2004	2000.2–2004.2	24	22	CAP/EP + cinobufacini injection	CAP/EP	Clinical efficacy, KPS, white blood cell
Yin XQ 2018	2013.1–2016.12	60	60	EP + cinobufacini injection	EP	Adverse event, clinical efficacy
Yu HY 2012	2009.6.1–2010.12.31	32	32	DP + cinobufacini injection	DP	Adverse event, clinical efficacy, KPS, median survival time, pain relief, weight change
Zang J 2001	NG	31	28	NG + cinobufacini injection	NG	Adverse event, clinical efficacy,
Zhang W 2011	2009.12–2010.12	46	30	Docetaxel + cinobufacini injection	Docetaxel	Adverse event, clinical efficacy, ECOG score